{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:54:44Z","timestamp":1792461284862,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by deficiency in arylsulfatase A (ASA) activity arising primarily from ASA gene (<jats:italic>ARSA<\/jats:italic>) variants. Late-infantile, juvenile and adult clinical subtypes are defined by symptom onset at\u2009\u2264\u20092.5,\u2009&gt;\u20092.5 to\u2009&lt;\u200916\u00a0and\u2009\u2265\u200916\u00a0years, respectively. Epidemiological data were sought to address knowledge gaps and to inform decisions regarding the clinical development of an investigational drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To synthesize all available estimates of MLD incidence and birth prevalence worldwide and in selected countries, Ovid MEDLINE and Embase were searched systematically (March 11, 2022) using a population, intervention, comparator, outcome, time and setting framework, complemented by pragmatic searching to reduce publication bias. Where possible, results were stratified by clinical subtype. Data were extracted from non-interventional studies (clinical trials, non-clinical studies and case reports were excluded; reviews were used for snowballing only).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 31 studies included, 14 reported birth prevalence (13 countries in Asia\u2013Pacific, Europe, the Middle East, North America and South America), one reported prevalence and none reported incidence. Birth prevalence per 100,000 live births ranged from 0.16 (Japan) to 1.85 (Portugal). In the three European studies with estimates stratified by clinical subtypes, birth prevalence was highest for late-infantile cases (0.31\u20131.12 per 100,000 live births). The distribution of clinical subtypes reported in cases diagnosed over various time periods in 17 studies varied substantially, but late-infantile and juvenile MLD accounted for at least two-thirds of cases in most studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This review provides a foundation for further analysis of the regional epidemiology of MLD. Data gaps indicate the need for better global coverage, increased use of epidemiological measures (e.g. prevalence estimates) and more stratification of outcomes by clinical and genetic disease subtype.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03044-w","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:02:32Z","timestamp":1708513352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A systematic review on the birth prevalence of metachromatic leukodystrophy"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-3191","authenticated-orcid":false,"given":"Shun-Chiao","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Bergamasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Bonnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teigna Arredondo","family":"Bison\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yola","family":"Moride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"2","key":"3044_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","volume":"29","author":"DF van Rappard","year":"2015","unstructured":"van Rappard DF, Boelens JJ, Wolf NI. Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab. 2015;29(2):261\u201373. https:\/\/doi.org\/10.1016\/j.beem.2014.10.001.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"457","key":"3044_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1651-2227.2008.00648.x","volume":"97","author":"V Gieselmann","year":"2008","unstructured":"Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr. 2008;97(457):15\u201321. https:\/\/doi.org\/10.1111\/j.1651-2227.2008.00648.x.","journal-title":"Acta Paediatr"},{"issue":"4","key":"3044_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1023\/B:NEUR.0000046572.53905.2c","volume":"33","author":"M Molander-Melin","year":"2004","unstructured":"Molander-Melin M, Pernber Z, Franken S, Gieselmann V, M\u00e5nsson J-E, Fredman P. Accumulation of sulfatide in neuronal and glial cells of arylsulfatase A deficient mice. J Neurocytol. 2004;33(4):417\u201327. https:\/\/doi.org\/10.1023\/B:NEUR.0000046572.53905.2c.","journal-title":"J Neurocytol"},{"key":"3044_CR4","doi-asserted-by":"publisher","first-page":"576221","DOI":"10.3389\/fmed.2020.576221","volume":"7","author":"AA Shaimardanova","year":"2020","unstructured":"Shaimardanova AA, Chulpanova DS, Solovyeva VV, Mullagulova AI, Kitaeva KV, Allegrucci C, et al. Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches. Front Med (Lausanne). 2020;7:576221. https:\/\/doi.org\/10.3389\/fmed.2020.576221.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3044_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13023-019-1060-2","volume":"14","author":"M Harrington","year":"2019","unstructured":"Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, et al. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis. 2019;14(1):89. https:\/\/doi.org\/10.1186\/s13023-019-1060-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3044_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/humu.22919","volume":"37","author":"M Cesani","year":"2016","unstructured":"Cesani M, Lorioli L, Grossi S, Amico G, Fumagalli F, Spiga I, et al. Mutation update of ARSA and PSAP genes causing metachromatic leukodystrophy. Hum Mutat. 2016;37(1):16\u201327. https:\/\/doi.org\/10.1002\/humu.22919.","journal-title":"Hum Mutat"},{"issue":"11","key":"3044_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/jnr.23792","volume":"94","author":"JB Rosenberg","year":"2016","unstructured":"Rosenberg JB, Kaminsky SM, Aubourg P, Crystal RG, Sondhi D. Gene therapy for metachromatic leukodystrophy. J Neurosci Res. 2016;94(11):1169\u201379. https:\/\/doi.org\/10.1002\/jnr.23792.","journal-title":"J Neurosci Res"},{"issue":"3","key":"3044_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ymgme.2005.07.010","volume":"86","author":"A Lugowska","year":"2005","unstructured":"Lugowska A, Amaral O, Berger J, Berna L, Bosshard NU, Chabas A, et al. Mutations c.459+1G>A and p.P426L in the ARSA gene: prevalence in metachromatic leukodystrophy patients from European countries. Mol Genet Metab. 2005;86(3):353\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2005.07.010.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3044_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10048-020-00621-6","volume":"21","author":"S Beerepoot","year":"2020","unstructured":"Beerepoot S, van Dooren SJM, Salomons GS, Boelens JJ, Jacobs EH, van der Knaap MS, et al. Metachromatic leukodystrophy genotypes in The Netherlands reveal novel pathogenic ARSA variants in non-Caucasian patients. Neurogenetics. 2020;21(4):289\u201399. https:\/\/doi.org\/10.1007\/s10048-020-00621-6.","journal-title":"Neurogenetics"},{"issue":"5","key":"3044_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1055\/s-0039-1692646","volume":"50","author":"P Madaan","year":"2019","unstructured":"Madaan P, Jauhari P, Chakrabarty B, Kumar A, Gulati S. Saposin B-deficient metachromatic leukodystrophy mimicking acute flaccid paralysis. Neuropediatrics. 2019;50(5):318\u201321. https:\/\/doi.org\/10.1055\/s-0039-1692646.","journal-title":"Neuropediatrics"},{"issue":"1","key":"3044_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0030-1253412","volume":"41","author":"V Gieselmann","year":"2010","unstructured":"Gieselmann V, Kr\u00e4geloh-Mann I. Metachromatic leukodystrophy\u2013an update. Neuropediatrics. 2010;41(1):1\u20136. https:\/\/doi.org\/10.1055\/s-0030-1253412.","journal-title":"Neuropediatrics"},{"issue":"2","key":"3044_CR12","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1212\/WNL.0000000000011047","volume":"96","author":"C Kehrer","year":"2021","unstructured":"Kehrer C, Elg\u00fcn S, Raabe C, B\u00f6hringer J, Beck-W\u00f6dl S, Bevot A, et al. Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodystrophy. Neurology. 2021;96(2):e255\u201366. https:\/\/doi.org\/10.1212\/WNL.0000000000011047.","journal-title":"Neurology"},{"issue":"2","key":"3044_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1469-8749.2010.03821.x","volume":"53","author":"C Kehrer","year":"2011","unstructured":"Kehrer C, Blumenstock G, Raabe C, Kr\u00e4geloh-Mann I. Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy. Dev Med Child Neurol. 2011;53(2):156\u201360. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03821.x.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"3044_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/acn3.420","volume":"4","author":"M Str\u00f6lin","year":"2017","unstructured":"Str\u00f6lin M, Kr\u00e4geloh-Mann I, Kehrer C, Wilke M, Groeschel S. Demyelination load as predictor for disease progression in juvenile metachromatic leukodystrophy. Ann Clin Transl Neurol. 2017;4(6):403\u201310. https:\/\/doi.org\/10.1002\/acn3.420.","journal-title":"Ann Clin Transl Neurol"},{"key":"3044_CR15","unstructured":"Orchard Therapeutics (Netherlands) B.V. Summary of product characteristics, Libmeldy. European Medicines Agency, 2020 (updated 2023). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/libmeldy-epar-product-information_en.pdf. Accessed Jan 2024."},{"issue":"1\u20132","key":"3044_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ymgme.2020.07.002","volume":"131","author":"C \u00cd Dali","year":"2020","unstructured":"\u00cd Dali\u00a0C, Sevin C, Kr\u00e4geloh-Mann I, Giugliani R, Sakai N, Wu J, et al. Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1\/2 clinical trial. Mol Genet Metab. 2020;131(1\u20132):235\u201344. https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.002.","journal-title":"Mol Genet Metab"},{"key":"3044_CR17","unstructured":"Gomez-Ospina N. Arylsulfatase A deficiency. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 2020."},{"issue":"12","key":"3044_CR18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/acn3.51692","volume":"9","author":"DH Schoenmakers","year":"2022","unstructured":"Schoenmakers DH, Beerepoot S, Kr\u00e4geloh-Mann I, Elg\u00fcn S, Bender B, van der Knaap MS, et al. Recognizing early MRI signs (or their absence) is crucial in diagnosing metachromatic leukodystrophy. Ann Clin Transl Neurol. 2022;9(12):1999\u20132009. https:\/\/doi.org\/10.1002\/acn3.51692.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"3044_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ajmg.1362","volume":"101","author":"S Holve","year":"2001","unstructured":"Holve S, Hu D, McCandless SE. Metachromatic leukodystrophy in the Navajo: fallout of the American-Indian wars of the nineteenth century. Am J Med Genet. 2001;101(3):203\u20138. https:\/\/doi.org\/10.1002\/ajmg.1362.","journal-title":"Am J Med Genet"},{"key":"3044_CR20","doi-asserted-by":"crossref","unstructured":"Samson D, Schoelles KM. Developing the topic and structuring systematic reviews of medical tests: utility of PICOTS, analytic frameworks, decision trees, and other frameworks. In: Chang SM, Matchar DB, Smetana GW, Umscheid CA, eds. Methods Guide for Medical Test Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012.","DOI":"10.1007\/s11606-012-2007-7"},{"key":"3044_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3044_CR22","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions, version 6.2. Cochrane Training, 2021. http:\/\/training.cochrane.org\/handbook. Accessed Dec 2021."},{"key":"3044_CR23","unstructured":"Institute of Medicine (US) Committee on Standards for Systematic Reviews of Comparative Effectiveness Research. Finding what works in health care: standards for systematic reviews. Eden J, Levit L, Berg A, Morton S, editors. Washington (DC): National Academies Press (US); 2011."},{"key":"3044_CR24","doi-asserted-by":"publisher","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Chapter 5: systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis. JBI; 2020. https:\/\/doi.org\/10.46658\/JBIMES-20-06.","DOI":"10.46658\/JBIMES-20-06"},{"issue":"1","key":"3044_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee","year":"2016","unstructured":"Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310. https:\/\/doi.org\/10.1002\/pds.3891.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"3044_CR26","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.ymgme.2019.11.040","volume":"129","author":"NA Bascou","year":"2020","unstructured":"Bascou NA, Carson V, Safonova A, Poe MD, Escolar ML. A prospective natural history study of metachromatic leukodystrophy: a 20 year study. Mol Genet Metab. 2020;129(2):S26\u20137.\u00a0https:\/\/doi.org\/10.1016\/j.ymgme.2019.11.040.","journal-title":"Mol Genet Metab"},{"key":"3044_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/2326409817722292","volume":"5","author":"A Lomash","year":"2017","unstructured":"Lomash A. Molecular insight, identification of novel genotype, establishment of genotype-phenotype correlation, and preparation of mutational dataset for metachromatic leukodystrophy of Indian ethnic population. J Inborn Errors Metab Screen. 2017;5:331.\u00a0https:\/\/doi.org\/10.1177\/232640981772229.","journal-title":"J Inborn Errors Metab Screen"},{"issue":"2","key":"3044_CR28","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.ymgme.2020.12.116","volume":"132","author":"S Jones","year":"2021","unstructured":"Jones S, Davison J, Mooney P, Campbell L, Baldock L, Wallington M, et al. Demographic and clinical characteristics of patients with metachromatic leukodystrophy in the United Kingdom: interim results from an observational real-world study. Mol Genet Metab. 2021;132(2):S53. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.116.","journal-title":"Mol Genet Metab"},{"key":"3044_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/8904_2012_182","volume":"10","author":"FA Al-Jasmi","year":"2013","unstructured":"Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Taleb M, Hertecant JL, et al. Prevalence and novel mutations of lysosomal storage disorders in United Arab Emirates\u202f: LSD in UAE. JIMD Rep. 2013;10:1\u20139. https:\/\/doi.org\/10.1007\/8904_2012_182.","journal-title":"JIMD Rep"},{"issue":"1","key":"3044_CR30","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.1.e10","volume":"105","author":"DA Applegarth","year":"2000","unstructured":"Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969\u20131996. Pediatrics. 2000;105(1):e10. https:\/\/doi.org\/10.1542\/peds.105.1.e10.","journal-title":"Pediatrics"},{"key":"3044_CR31","doi-asserted-by":"publisher","first-page":"100344","DOI":"10.1016\/j.lanwpc.2021.100344","volume":"19","author":"SJ Chin","year":"2022","unstructured":"Chin SJ, Fuller M. Prevalence of lysosomal storage disorders in Australia from 2009 to 2020. Lancet Reg Health West Pac. 2022;19:100344. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100344.","journal-title":"Lancet Reg Health West Pac"},{"issue":"12","key":"3044_CR32","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/apa.12807","volume":"103","author":"M Hult","year":"2014","unstructured":"Hult M, Darin N, von D\u00f6beln U, M\u00e5nsson J-E. Epidemiology of lysosomal storage diseases in Sweden. Acta Paediatr. 2014;103(12):1258\u201363. https:\/\/doi.org\/10.1111\/apa.12807.","journal-title":"Acta Paediatr"},{"issue":"3","key":"3044_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354. https:\/\/doi.org\/10.1001\/jama.281.3.249.","journal-title":"JAMA"},{"issue":"1\u20132","key":"3044_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJHM Poorthuis","year":"1999","unstructured":"Poorthuis BJHM, Wevers RA, Kleijer WJ, Groener JE, de Jong JGN, van Weely S, et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet. 1999;105(1\u20132):151\u20136. https:\/\/doi.org\/10.1007\/s004399900075.","journal-title":"Hum Genet"},{"issue":"3","key":"3044_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1096-8628(19970331)69:3<335::AID-AJMG22>3.0.CO;2-R","volume":"69","author":"J Berger","year":"1997","unstructured":"Berger J, L\u00f6schl B, Bernheimer H, Lugowska A, Tylki-Szymanska A, Gieselmann V, et al. Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. Am J Med Genet. 1997;69(3):335\u201340.","journal-title":"Am J Med Genet"},{"issue":"7","key":"3044_CR36","doi-asserted-by":"publisher","first-page":"e185031","DOI":"10.1001\/jamanetworkopen.2018.5031","volume":"1","author":"JL Bonkowsky","year":"2018","unstructured":"Bonkowsky JL, Wilkes J, Bardsley T, Urbik VM, Stoddard G. Association of diagnosis of leukodystrophy with race and ethnicity among pediatric and adolescent patients. JAMA Netw Open. 2018;1(7):e185031. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.5031.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3044_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1590\/1678-4685-GMB-2016-0268","volume":"40","author":"R Giugliani","year":"2017","unstructured":"Giugliani R, Federhen A, Michelin-Tirelli K, Riegel M, Burin M. Relative frequency and estimated minimal frequency of lysosomal storage diseases in Brazil: report from a reference laboratory. Genet Mol Biol. 2017;40(1):31\u20139. https:\/\/doi.org\/10.1590\/1678-4685-GMB-2016-0268.","journal-title":"Genet Mol Biol"},{"issue":"4","key":"3044_CR38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/(SICI)1096-8628(19970905)71:4<475::AID-AJMG20>3.0.CO;2-C","volume":"71","author":"P Heim","year":"1997","unstructured":"Heim P, Claussen M, Hoffmann B, Conzelmann E, G\u00e4rtner J, Harzer K, et al. Leukodystrophy incidence in Germany. Am J Med Genet. 1997;71(4):475\u20138.","journal-title":"Am J Med Genet"},{"issue":"3","key":"3044_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ymgme.2021.05.004","volume":"133","author":"Y Koto","year":"2021","unstructured":"Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, et al. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan. Mol Genet Metab. 2021;133(3):277\u201388. https:\/\/doi.org\/10.1016\/j.ymgme.2021.05.004.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3044_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1399-0004.2005.00451.x","volume":"68","author":"A \u0141ugowska","year":"2005","unstructured":"\u0141ugowska A, Berger J, Tylki-Szyma\u0144ska A, L\u00f6schl B, Molzer B, Zobel M, et al. Molecular and phenotypic characteristics of metachromatic leukodystrophy patients from Poland. Clin Genet. 2005;68(1):48\u201354. https:\/\/doi.org\/10.1111\/j.1399-0004.2005.00451.x.","journal-title":"Clin Genet"},{"issue":"6","key":"3044_CR41","doi-asserted-by":"publisher","first-page":"e20218","DOI":"10.1371\/journal.pone.0020218","volume":"6","author":"A \u0141ugowska","year":"2011","unstructured":"\u0141ugowska A, Poni\u0144ska J, Krajewski P, Broda G, P\u0142oski R. Population carrier rates of pathogenic ARSA gene mutations: is metachromatic leukodystrophy underdiagnosed? PLoS ONE. 2011;6(6):e20218. https:\/\/doi.org\/10.1371\/journal.pone.0020218.","journal-title":"PLoS ONE"},{"issue":"4","key":"3044_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s10038-019-0560-1","volume":"64","author":"DL Narayanan","year":"2019","unstructured":"Narayanan DL, Matta D, Gupta N, Kabra M, Ranganath P, Aggarwal S, et al. Spectrum of ARSA variations in Asian Indian patients with arylsulfatase A deficient metachromatic leukodystrophy. J Hum Genet. 2019;64(4):323\u201331. https:\/\/doi.org\/10.1038\/s10038-019-0560-1.","journal-title":"J Hum Genet"},{"issue":"6","key":"3044_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.braindev.2003.09.006","volume":"26","author":"HA Ozkara","year":"2004","unstructured":"Ozkara HA, Top\u00e7u M. Sphingolipidoses in Turkey. Brain Dev. 2004;26(6):363\u20136. https:\/\/doi.org\/10.1016\/j.braindev.2003.09.006.","journal-title":"Brain Dev"},{"issue":"2","key":"3044_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","volume":"12","author":"R Pinto","year":"2004","unstructured":"Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12(2):87\u201392. https:\/\/doi.org\/10.1038\/sj.ejhg.5201044.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"3044_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1056\/NEJM199101033240104","volume":"324","author":"A Polten","year":"1991","unstructured":"Polten A, Fluharty AL, Fluharty CB, Kappler J, von Figura K, Gieselmann V. Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med. 1991;324(1):18\u201322. https:\/\/doi.org\/10.1056\/NEJM199101033240104.","journal-title":"N Engl J Med"},{"issue":"4","key":"3044_CR46","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10545-010-9093-7","volume":"33","author":"H Poup\u011btov\u00e1","year":"2010","unstructured":"Poup\u011btov\u00e1 H, Ledvinov\u00e1 J, Bern\u00e1 L, Dvo\u0159\u00e1kov\u00e1 L, Ko\u017eich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 2010;33(4):387\u201396. https:\/\/doi.org\/10.1007\/s10545-010-9093-7.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"3044_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jns.2010.11.007","volume":"301","author":"P Shukla","year":"2011","unstructured":"Shukla P, Vasisht S, Srivastava R, Gupta N, Ghosh M, Kumar M, et al. Molecular and structural analysis of metachromatic leukodystrophy patients in Indian population. J Neurol Sci. 2011;301(1\u20132):38\u201345. https:\/\/doi.org\/10.1016\/j.jns.2010.11.007.","journal-title":"J Neurol Sci"},{"issue":"7","key":"3044_CR48","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/dmcn.13027","volume":"58","author":"LA Stellitano","year":"2016","unstructured":"Stellitano LA, Winstone AM, van der Knaap MS, Verity CM. Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study. Dev Med Child Neurol. 2016;58(7):680\u20139. https:\/\/doi.org\/10.1111\/dmcn.13027.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"3044_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.gene.2015.05.016","volume":"568","author":"MYF Virgens","year":"2015","unstructured":"Virgens MYF, Siebert M, Bock H, Burin M, Giugliani R, Saraiva-Pereira ML. Genotypic characterization of Brazilian patients with infantile and juvenile forms of metachromatic leukodystrophy. Gene. 2015;568(1):69\u201375. https:\/\/doi.org\/10.1016\/j.gene.2015.05.016.","journal-title":"Gene"},{"issue":"12","key":"3044_CR50","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1177\/0883073809341269","volume":"24","author":"ZN Al-Hassnan","year":"2009","unstructured":"Al-Hassnan ZN, Al Dhalaan H, Patay Z, Faqeih E, Al-Owain M, Al-Duraihem A, et al. Sphingolipid activator protein B deficiency: report of 9 Saudi patients and review of the literature. J Child Neurol. 2009;24(12):1513\u20139. https:\/\/doi.org\/10.1177\/0883073809341269.","journal-title":"J Child Neurol"},{"issue":"1","key":"3044_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00230227","volume":"91","author":"ML Barth","year":"1993","unstructured":"Barth ML, Fensom A, Harris A. Prevalence of common mutations in the arylsulphatase A gene in metachromatic leukodystrophy patients diagnosed in Britain. Hum Genet. 1993;91(1):73\u20137. https:\/\/doi.org\/10.1007\/BF00230227.","journal-title":"Hum Genet"},{"issue":"4","key":"3044_CR52","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1399-0004.2008.01058.x","volume":"74","author":"A Biffi","year":"2008","unstructured":"Biffi A, Cesani M, Fumagalli F, Del Carro U, Baldoli C, Canale S, et al. Metachromatic leukodystrophy \u2013 mutation analysis provides further evidence of genotype\u2013phenotype correlation. Clin Genet. 2008;74(4):349\u201357. https:\/\/doi.org\/10.1111\/j.1399-0004.2008.01058.x.","journal-title":"Clin Genet"},{"issue":"1","key":"3044_CR53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1186\/s13104-019-4773-3","volume":"12","author":"D Hettiarachchi","year":"2019","unstructured":"Hettiarachchi D, Dissanayake VHW. Three novel variants in the arylsulfatase A (ARSA) gene in patients with metachromatic leukodystrophy (MLD). BMC Res Notes. 2019;12(1):726. https:\/\/doi.org\/10.1186\/s13104-019-4773-3.","journal-title":"BMC Res Notes"},{"key":"3044_CR54","doi-asserted-by":"publisher","first-page":"106448","DOI":"10.1016\/j.clineuro.2020.106448","volume":"201","author":"N Mahdieh","year":"2021","unstructured":"Mahdieh N, Sharifi A, Rabbani A, Ashrafi M, Tavasoli AR, Badv RS, et al. Novel disease-causing variants in a cohort of Iranian patients with metachromatic leukodystrophy and in silico analysis of their pathogenicity. Clin Neurol Neurosurg. 2021;201:106448. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106448.","journal-title":"Clin Neurol Neurosurg"},{"key":"3044_CR55","unstructured":"Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World Population Prospects 2022.  United Nations, 2022. https:\/\/population.un.org\/wpp\/. Accessed 29 Nov 2023."},{"key":"3044_CR56","doi-asserted-by":"publisher","first-page":"e25212","DOI":"10.4161\/rdis.25212","volume":"1","author":"AH Foss","year":"2013","unstructured":"Foss AH, Duffner PK, Carter RL. Lifetime risk estimators in epidemiological studies of Krabbe disease: review and Monte Carlo comparison. Rare Dis. 2013;1:e25212. https:\/\/doi.org\/10.4161\/rdis.25212.","journal-title":"Rare Dis"},{"key":"3044_CR57","unstructured":"Oliva P, Mechtler T, Schwarz M, Streubel B, Chanson C, Essing MM, et al. Newborn screening for metachromatic leukodystrophy in Northern Germany\u2014a prospective study. Presented at the 19th Annual WORLD Symposium\u2122, Orlando, FL, USA, 22\u201326 February 2023."},{"issue":"3","key":"3044_CR58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1479-7364-5-3-156","volume":"5","author":"M Filocamo","year":"2011","unstructured":"Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics. 2011;5(3):156\u201369. https:\/\/doi.org\/10.1186\/1479-7364-5-3-156.","journal-title":"Hum Genomics"},{"issue":"3","key":"3044_CR59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ymgme.2022.09.009","volume":"137","author":"V Santhanakumaran","year":"2022","unstructured":"Santhanakumaran V, Groeschel S, Harzer K, Kehrer C, Elg\u00fcn S, Beck-W\u00f6dl S, et al. Predicting clinical phenotypes of metachromatic leukodystrophy based on the arylsulfatase A activity and the ARSA genotype?: Chances and challenges. Mol Genet Metab. 2022;137(3):273\u201382. https:\/\/doi.org\/10.1016\/j.ymgme.2022.09.009.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3044_CR60","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s12031-019-1259-7","volume":"67","author":"M Kolnikova","year":"2019","unstructured":"Kolnikova M, Jungova P, Skopkova M, Foltan T, Gasperikova D, Mattosova S, et al. Late infantile metachromatic leukodystrophy due to novel pathogenic variants in the PSAP gene. J Mol Neurosci. 2019;67(4):559\u201363. https:\/\/doi.org\/10.1007\/s12031-019-1259-7.","journal-title":"J Mol Neurosci"},{"issue":"1","key":"3044_CR61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","volume":"12","author":"J Muenzer","year":"2017","unstructured":"Muenzer J, Jones SA, Tylki-Szyma\u0144ska A, Harmatz P, Mendelsohn NJ, Guffon N, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2017;12(1):82. https:\/\/doi.org\/10.1186\/s13023-017-0635-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3044_CR62","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","volume":"17","author":"M Beck","year":"2022","unstructured":"Beck M, Ramaswami U, Hernberg-St\u00e5hl E, Hughes DA, Kampmann C, Mehta AB, et al. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2022;17(1):238. https:\/\/doi.org\/10.1186\/s13023-022-02392-9","journal-title":"Orphanet J Rare Dis"},{"key":"3044_CR63","unstructured":"The MLD initiative. The MLD initiative \u2013 disease registry for metachromatic leukodystrophy. https:\/\/www.mldinitiative.com\/. Accessed Jan 2024."},{"issue":"3","key":"3044_CR64","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41436-020-01017-5","volume":"23","author":"X Hong","year":"2021","unstructured":"Hong X, Daiker J, Sadilek M, Ruiz-Schultz N, Kumar AB, Norcross S, et al. Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots. Genet Med. 2021;23(3):555\u201361. https:\/\/doi.org\/10.1038\/s41436-020-01017-5.","journal-title":"Genet Med"},{"issue":"9","key":"3044_CR65","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/clinchem\/46.9.1318","volume":"46","author":"K Umapathysivam","year":"2000","unstructured":"Umapathysivam K, Whittle AM, Ranieri E, Bindloss C, Ravenscroft EM, van Diggelen OP, et al. Determination of acid \u03b1-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem. 2000;46(9):1318\u201325.\u00a0https:\/\/doi.org\/10.1093\/clinchem\/46.9.1318.","journal-title":"Clin Chem"},{"issue":"4","key":"3044_CR66","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/jmd2.12293","volume":"63","author":"L Laugwitz","year":"2022","unstructured":"Laugwitz L, Santhanakumaran V, Spieker M, Boehringer J, Bender B, Gieselmann V, et al. Extremely low arylsulfatase A enzyme activity does not necessarily cause symptoms: a long-term follow-up and review of the literature. JIMD Rep. 2022;63(4):292\u2013302. https:\/\/doi.org\/10.1002\/jmd2.12293.","journal-title":"JIMD Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03044-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03044-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03044-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:05:47Z","timestamp":1708513547000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03044-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03044-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new ethics approval was needed to comply with ethical standards since no new data were generated. No new patient consent was needed since no new data were generated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S-CC is an employee of Takeda Development Center Americas, Inc. and is a stockholder of Takeda Pharmaceutical Company Limited. AB, MB, TAB and YM have participated in advisory boards or are consultants for Takeda and are employees of YOLARX Consultants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}